Healthcare provider profile · identity verified

Yadira Rodriguez

Physician Assistant · SAN ANTONIO, TX · NPI 1376848952

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	356	171
Metformin Hcl	Metformin Hcl	309	122
Fluticasone Propionate	Fluticasone Propionate	280	94
Amlodipine Besylate	Amlodipine Besylate	270	127
Gabapentin	Gabapentin	270	126
Montelukast Sodium	Montelukast Sodium	250	109
Levothyroxine Sodium	Levothyroxine Sodium	204	69
Lisinopril	Lisinopril	202	101
Ozempic	Semaglutide	188	66
Losartan Potassium	Losartan Potassium	180	75
Rosuvastatin Calcium	Rosuvastatin Calcium	178	80
Pravastatin Sodium	Pravastatin Sodium	166	67
Albuterol Sulfate Hfa	Albuterol Sulfate	163	62
Pantoprazole Sodium	Pantoprazole Sodium	152	68
Carvedilol	Carvedilol	151	69
Farxiga	Dapagliflozin Propanediol	145	66
Hydrochlorothiazide	Hydrochlorothiazide	130	60
Metoprolol Succinate	Metoprolol Succinate	126	48
Omeprazole	Omeprazole	123	48
Metformin Hcl Er	Metformin Hcl	119	55
Tamsulosin Hcl	Tamsulosin Hcl	111	50
Mounjaro	Tirzepatide	102	30
Enalapril Maleate	Enalapril Maleate	100	46
Furosemide	Furosemide	100	60
Trazodone Hcl	Trazodone Hcl	98	35
Jardiance	Empagliflozin	95	47
Escitalopram Oxalate	Escitalopram Oxalate	92	42
Metoprolol Tartrate	Metoprolol Tartrate	92	34
Esomeprazole Magnesium	Esomeprazole Magnesium	89	38
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	84	38
Hydroxyzine Hcl	Hydroxyzine Hcl	83	44
Simvastatin	Simvastatin	73	31
Famotidine	Famotidine	69	33
Trulicity	Dulaglutide	69	26
Baclofen	Baclofen	68	27
Sertraline Hcl	Sertraline Hcl	66	28
Glipizide	Glipizide	63	29
Eliquis	Apixaban	60	23
Alendronate Sodium	Alendronate Sodium	56	22
Finasteride	Finasteride	56	26
Lidocaine	Lidocaine	55	22
Tradjenta	Linagliptin	54	25
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	52	22
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	52	19
Linzess	Linaclotide	51	21
Clopidogrel	Clopidogrel Bisulfate	50	24
Tresiba Flextouch U-100	Insulin Degludec	49	19
Symbicort	Budesonide/Formoterol Fumarate	47	13
Pregabalin	Pregabalin	44	23
Ezetimibe	Ezetimibe	43	20
Advair Hfa	Fluticasone Propion/Salmeterol	42	15
Pioglitazone Hcl	Pioglitazone Hcl	42	19
Ventolin Hfa	Albuterol Sulfate	42	24
Meclizine Hcl	Meclizine Hcl	41	16
Tramadol Hcl	Tramadol Hcl	38	21
Vitamin D2	Ergocalciferol (Vitamin D2)	37	17
Nifedipine Er	Nifedipine	35	20
Tizanidine Hcl	Tizanidine Hcl	35	12
Spironolactone	Spironolactone	34	15
Duloxetine Hcl	Duloxetine Hcl	33	16
Allopurinol	Allopurinol	32	13
Januvia	Sitagliptin Phosphate	32	15
Azelastine Hcl	Azelastine Hcl	31	13
Ciclopirox	Ciclopirox Olamine	31	19
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	30	28
Fluoxetine Hcl	Fluoxetine Hcl	30	15
Humalog Kwikpen U-100	Insulin Lispro	30	13
Ibuprofen	Ibuprofen	28	19
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	28	12
Paroxetine Hcl	Paroxetine Hcl	28	11
Chlorthalidone	Chlorthalidone	27	11
Clobetasol Propionate	Clobetasol Propionate	27	12
Diclofenac Sodium	Diclofenac Sodium	27	20
Dicyclomine Hcl	Dicyclomine Hcl	27	suppressed
Ondansetron Odt	Ondansetron	27	16
Atenolol	Atenolol	26	suppressed
Rybelsus	Semaglutide	25	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	25	11
Fluconazole	Fluconazole	23	15
Ammonium Lactate	Ammonium Lactate	21	suppressed
Celecoxib	Celecoxib	21	15
Hydralazine Hcl	Hydralazine Hcl	21	suppressed
Mupirocin	Mupirocin	21	20
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	21	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	20	suppressed
Vascepa	Icosapent Ethyl	20	suppressed
Ketoconazole	Ketoconazole	19	suppressed
Nitroglycerin	Nitroglycerin	19	14
Econazole Nitrate	Econazole Nitrate	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	18	15
Acetaminophen-Codeine	Acetaminophen With Codeine	17	11
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Gemfibrozil	Gemfibrozil	17	suppressed
Levemir Flexpen	Insulin Detemir	17	suppressed
Glimepiride	Glimepiride	16	suppressed
Lovastatin	Lovastatin	16	suppressed
Meloxicam	Meloxicam	16	suppressed
Sildenafil Citrate	Sildenafil Citrate	16	suppressed
Valsartan	Valsartan	16	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	15	suppressed
Ipratropium Bromide	Ipratropium Bromide	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	14	suppressed
Glipizide Er	Glipizide	14	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	14	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	14	suppressed
Mirtazapine	Mirtazapine	14	suppressed
Novolog Flexpen	Insulin Aspart	14	suppressed
Indapamide	Indapamide	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Levetiracetam	Levetiracetam	12	suppressed
Terazosin Hcl	Terazosin Hcl	12	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Cephalexin	Cephalexin	11	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	11	suppressed
Fosinopril Sodium	Fosinopril Sodium	11	suppressed
Incontrol Pen Needle	Pen Needle, Diabetic	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Sucralfate	Sucralfate	11	suppressed
Sure Comfort Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error